Does pre‐operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post‐operative morbidity? A case‐matched analysis. Issue 8 (10th January 2013)

• Record Type: Journal Article
• Authors: Araujo, Raphael L. C.; Gaujoux, Sébastien; Huguet, Florence; Gonen, Mithat; D'Angelica, Michael I.; DeMatteo, Ronald P.; Fong, Yuman; Kingham, T. Peter; Jarnagin, William R.; Goodman, Karyn A.; Allen, Peter J.
• Is Part Of: HPB. Volume 15:Issue 8(2013:Aug.)
• Page Start: 574
• Page End: 580
• Publication Date: 2013-01-10
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1111/hpb.12033
• Languages: English
• ISSNs: 1365-182X

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="hpb12033-sec-0001" sec-type="section"> <title>Background</title> <p>Neoadjuvant chemoradiation therapy for locally unresectable and borderline resectable pancreatic cancer may allow some patients to a undergo a resection, but whether or not this increases post‐operative morbidity remains unclear.</p> </sec> <sec id="hpb12033-sec-0002" sec-type="section"> <title>Methods</title> <p>The post‐operative morbidity of 29 patients with initially locally unresectable/borderline pancreatic cancer who underwent a resection were compared with 29 patients with initially resectable tumours matched for age, gender, the presence of comorbidities (yes/no), American Society of Anesthesiology (ASA) score, tumour location (head/body‐tail), procedure (pancreaticoduodenectomy/distal pancreatectomy) and vascular resection (yes /no). Wilcoxon's signed ranks test was used for continuous variables and McNemar's chi‐square test for categorical variables.</p> </sec> <sec id="hpb12033-sec-0003" sec-type="section"> <title>Results</title> <p>Compared with patients with initially resectable tumours, patients who underwent a resection after pre‐operative chemoradiation therapy had similar rates of overall post‐operative complications (55% versus 41%, <italic>P</italic> = 0.42), major complications (21% versus 21%, <italic>P</italic> = 1), pancreatic leaks and fistulae (7% versus 10%, <italic>P</italic> = 1) and mortality (0% versus 1.7%, <italic>P</italic> = 1).</p> </sec> <sec id="hpb12033-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Although some previous studies have suggested differences in post‐operative morbidity after chemoradiation, our case‐matched analysis did not find statistical differences in surgical morbidity and mortality associated with pre‐operative chemoradiation therapy.</p> </sec> </abstract>